What did Atlas Arteria report?

• The IFM Takeover Offer closed on 7 July 2026, with the bidder securing 67.43% of Atlas Arteria's voting power.
• Debbie Goodin retired as Independent Non-executive Chair and Director after the offer closure.
• John Wigglesworth appointed Interim Chair of Atlas Arteria Limited and Non-executive Director of Atlas Arteria International Limited.
• Jean-Georges Malcor appointed Chair of the Audit and Risk Committee.
• The board is accelerating its search for a new independent Chair, considering both internal and external candidates.

What else do investors need to know?

The board has reaffirmed its approach to related party transactions, emphasising that any potential conflicts of interest or material transactions involving IFM will continue to be overseen by independent directors. This is in line with Atlas Arteria's established practices and existing agreements.

Atlas Arteria also operates an international portfolio, including toll road businesses in France, Germany and the United States. The company's focus remains on disciplined management and delivering long-term value for investors.

What did Atlas Arteria management say?

Interim Chair John Wigglesworth said:

We are entering a crucial period for Atlas Arteria. As we look ahead after the closure of the takeover offer, the Boards recognise the importance of focusing on optimising value for our investors. We thank Debbie for her significant contribution to Atlas Arteria over many years. Her support for a smooth transition has underscored her relentless commitment to act in the best interests of all securityholders. While the process for determining a new independent Chair of ATLAX continues, I am committed to engaging constructively with IFM.

What's next for Atlas Arteria?

The board recruitment process for a new permanent Chair is underway, with both internal and external candidates being considered. Until an appointment is made, John Wigglesworth will act as Interim Chair and work constructively with IFM and other stakeholders.

Reflecting its new ownership, Atlas Arteria will maintain strong governance practices around related party decisions and continue to focus on sustainable business practices across its international toll road assets.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have risen 1%, slightly trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.

View Original Announcement

The post Atlas Arteria closes IFM takeover and begins board renewal appeared first on The Motley Fool Australia.

For investors who are looking for an income stream rather than capital gains, it pays to go with Australian-based companies that have committed to paying dividends over the medium to long term, and exchange-traded funds specifically set up to pay high dividends.

How much do you need to generate $500 per week?

So, let's look at the yields you'll need for a $500 per week return. This, of course, translates to $26,000 a year.

So, what dividend yields do stocks normally pay?

According to S&P Dow Jones, the S&P/ASX 200 Index (ASX: XJO) delivered an average trailing dividend yield of 4.15% from July 2011 to December 2024.

But this includes plenty of companies that pay low or no dividends.

I'd argue it's quite possible to aim for a portfolio that delivers a dividend yield of around 5%, while also including some companies that pay a lot more.

At a 5% yield, you'd need a portfolio worth $520,000 to deliver $500 a week.

At a 7.5% yield you'd need just $346,666.

At a 10% yield you'd need just $260,000.

While there are stocks which pay more than a 10% yield, these are few and far between, and I'd argue that those sorts of yields are likely to be unsustainable.

What ASX shares can I invest in to achieve $500 in income?

On the ETF front, the Australian Dividend Harvester Active ETF (ASX: HVST) is currently paying a yield of 5.8%, which sits firmly in the ballpark of returns targeted.

There is also the Vanguard Australian Shares High Yield ETF (ASX: VHY) which has major holdings in BHP Group Ltd (ASX: BHP), Commonwealth Bank of Australia (ASX: CBA) and Rio Tinto Ltd (ASX: RIO).

This ETF currently pays a dividend yield of 5.47%.

Another income-focused security is WAM Capital Ltd (ASX: WAM), which is currently paying a trailing dividend of 10.4%, 60% franked.

Among the miners Fortescue Ltd (ASX: FMG) pays a healthy trailing dividend of 6.37% currently, while toll roads operator Atlas Arteria Ltd (ASX: ALX) – should it survive a current takeover approach – has committed to paying a dividend of 60 cents per share, or well over 10%.

Three other companies which are currently paying out better than 5% dividends are AGL Energy Ltd (ASX: AGL), APA Group (ASX: APA), and Stockland Corporation Ltd (ASX: SGP).

Other solid companies which pay a bit less than we're after are Telstra Ltd (ASX: TLS) with a yield of 3.93% and Westpac Banking Corporation (ASX: WBC) which pays a trailing yield of 4.37%.

So as you can see, with some diversification across stocks such as these, a 5% dividend yield appears to be within reach.

The post How to get started with a portfolio delivering $500 a week in passive income appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• The US District Court dismissed the Dulles Greenway 2024 rate case litigation against TRIP II.
• TRIP II is reviewing the decision and considering an appeal.
• Legislative reforms now allow for two-year toll applications and set defined timelines for regulatory decisions.
• The latest Dulles Greenway rate case, submitted in December 2025, continues as scheduled.

What else do investors need to know?

The dismissal relates directly to Atlas Arteria's Dulles Greenway asset in the US, part of its portfolio spanning France, Germany, and the United States. Earlier this year, regulatory changes were enacted in Virginia that make toll application processes faster and more predictable, which could reduce costs and improve planning for the company.

Atlas Arteria remains active in engaging with the Commonwealth of Virginia, local governments, and communities to build and maintain positive partnerships. Its approach emphasises long-term stakeholder and shareholder value through constructive engagement and disciplined management.

What's next for Atlas Arteria?

Atlas Arteria's focus is now on evaluating legal options while working within the revised regulatory environment in Virginia. The latest toll rate application process is continuing, and management says it is progressing in line with schedules.

The company has reiterated its commitment to sustainable business practices and stakeholder value, signalling ongoing dialogue with authorities and communities across its global portfolio.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have remained flat, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Atlas Arteria reacts to Dulles Greenway litigation outcome appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• The takeover offer from IFM Investors has been extended by 14 days, now closing on 7 July 2026.
• Diamond Infraco 1 Pty Ltd, an IFM Investors subsidiary, has acquired voting power greater than 50% in Atlas Arteria.
• The Independent Directors are reviewing the offer and intend to release a supplementary statement before market open on 29 June 2026.
• Atlas Arteria remains committed to acting in the interests of all securityholders.

What else do investors need to know?

Atlas Arteria currently owns and operates toll road assets across France, Germany, and the United States, including key stakes in APRR, AREA, Chicago Skyway, Dulles Greenway, and Warnow Tunnel. The update on the takeover process signals a key turning point, with majority ownership now passing to the bidder.
The Independent Board Committee and International Board have authorised the announcement and are considering their next steps carefully. Ongoing communication with stakeholders will continue throughout the process.

What's next for Atlas Arteria?

Atlas Arteria's Independent Directors are preparing a supplementary Target's Statement, expected to be released before the market opens on 29 June 2026. Shareholders can expect additional guidance on the response to the IFM offer in this announcement.
Looking ahead, the company remains focused on safeguarding value for all its securityholders while ensuring continued operations across its global toll road network.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 2%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Atlas Arteria shares: IFM extends takeover offer after passing 50% voting power appeared first on The Motley Fool Australia.

For those who are targeting high dividends, it pays to keep an eye out for the stocks and funds that are paying out well, but which can still be bought cheaply on a yield basis.

I've selected three that might fit the bill. Let's have a look.

Ophir High Conviction Fund (ASX: OPH)

The Ophir High Conviction Fund only pays out a dividend once a year. The good news is it's not too late to buy in.

The ex-dividend date for the upcoming 35.17-cent-per-share dividend is June 30, so you'd have to move relatively quickly to be able to take advantage of it.

Given the Ophir share price is currently $2.86, the shares are paying a dividend yield of 12.3%.

It must be said that the shares are currently down 13.9% over a 12-month period, and are trading at a discount to the fund's net asset value of $3.18.

Ophir's top five holdings are in A2 Milk Company Ltd (ASX: A2M), MAAS Group Holdings Ltd (ASX: MGH), Mineral Resources Ltd (ASX: MIN), ResMed Inc (ASX: RMD), and SuperLoop Ltd (ASX: SLC).

Atlas Arteria Ltd (ASX: ALX)

Atlas Arteria has announced a 50% boost to its full-year dividend payout as it moves to fend off a takeover bid from Diamond Infraco.

The toll roads operator previously had a dividend target of 40 cents per share, but on Monday morning, it said in a statement to the ASX that this target would be increased to 60 cents per share.

At the company's current share price of $5.10, that equates to a full-year dividend yield of 11.8%.

The company said on Monday:

The Independent Directors now intend to target paying distributions to ALX Securityholders of at least 60.0 cents per ALX Security in the 12 months following the end of the Offer Period made up of ordinary distributions of 40.0 cents per ALX Security and additional distributions of at least 20.0 cents per ALX Security. These distributions are expected to be funded by a combination of distributions from Atlas Arteria's portfolio cash flows, proceeds from potential asset sales and, where appropriate, utilising corporate borrowing proceeds.

WAM Capital Ltd (ASX: WAM)

This fund has paid out a 7.75-cent dividend twice a year like clockwork in recent times, giving it a dividend yield of 10.1%.

Part of well-known investor Geoff Wilson's stable, the fund's portfolio has returned an annualised 14.5% return since 1999, compared with 8.5% for the S&P/ASX All Ordinaries Index (ASX: XAO).

The fund said in a recent statement that one of its top performers had been network-as-a-service provider Megaport Ltd (ASX: MP1), while telco Tuas Ltd (ASX: TUA) was a drag on the portfolio.

The post Targeting a dividend yield above 10%? Try these shares on for size appeared first on The Motley Fool Australia.

Already generous dividend increased further

The toll roads operator previously had a dividend target of 40 cents per share, but on Monday morning, it said in a statement to the ASX that this target would be increased to 60 cents per share.

The company said:

The Independent Directors now intend to target paying distributions to ALX Securityholders of at least 60.0 cents per ALX Security in the 12 months following the end of the Offer Period made up of ordinary distributions of 40.0 cents per ALX Security and additional distributions of at least 20.0 cents per ALX Security. These distributions are expected to be funded by a combination of distributions from Atlas Arteria's portfolio cash flows, proceeds from potential asset sales and, where appropriate, utilising corporate borrowing proceeds.

The offer period refers to Diamond Infraco's $5.10 per share takeover offer, which Atlas Arteria's directors are recommending shareholders reject.

Atlas Arteria said the increased dividends would likely have the effect of reducing dividends further out by 2 cents per share.

The company also said it was engaging in more discussions around asset sales.

The company said:

Atlas Arteria continues to progress initiatives to unlock value from its portfolio of world-class assets. In addition to progressing the potential divestment of the Chicago Skyway, Atlas Arteria has entered into exclusive discussions with Eiffage S.A., a leading French concession and construction group, in relation to the potential sale of Atlas Arteria's 100% stake in the Warnow Tunnel in Germany. In the event a sale to Eiffage proceeds, Atlas Arteria expects that the sale price will be consistent with the Independent Expert's range of €100m to €115m. Warnow Tunnel is the smallest asset in Atlas Arteria's portfolio, and the possible divestment will not have a material impact on the future strategy of the group.

Diamond Infraco recently said its $5.10 per share offer for the company was its best and final offer.

Shares are worth more, company says

Atlas Arteria said in its statement on Monday that, "the Offer continues to materially undervalue Atlas Arteria and does not reflect an appropriate control premium for ALX Securityholders''.

An independent expert's report has concluded that the offer is neither fair nor reasonable, and that an appropriate value for Atlas Arteria would be $5.39 to $6.20 per share.

Atlas Arteria shares were changing hands for $5.10 on Monday morning. At that price, the 60-cent per share dividend equates to a dividend yield of 11.8%.

The post How does an 11.8% dividend yield sound? appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• Diamond Infraco 1 Pty Ltd's offer price of A$5.10 per security is best and final, and will not be increased (in the absence of a competing proposal).
• The offer is now unconditional, removing all previous conditions to acceptance.
• Bidder's current voting power in Atlas Arteria stands at 38.42% as of 17 June 2026.
• Securityholders can accept the offer or sell on-market at A$5.10 per security, with settlement in T+2.
• The offer closes 7.00pm (Sydney time) on 25 June 2026 and will not be extended except if required by law.

What else do investors need to know?

The bidder has made a binding 'truth-in-takeovers' statement that it will not acquire Atlas Arteria securities at more than A$5.10 per security for at least 12 months after the offer closes, unless a competing proposal arises. Any distributions paid during this period would reduce the maximum price in subsequent acquisitions by Diamond Infraco 1 Pty Ltd.

Investors are being urged to act now, as there is no certainty Diamond Infraco 1 Pty Ltd will acquire further securities after the close, and any future acquisitions could be at lower prices. The offer window provides a liquidity option at a material premium to undisturbed prices (A$4.33 per security).

What's next for Atlas Arteria?

Looking ahead, securityholders face a decision between accepting the current cash offer or retaining exposure to the company's assets and strategies, including any future sale of Chicago Skyway. The bidder notes there is significant uncertainty over asset sales and the potential for security price weakness after the close of the offer, alongside ongoing company-specific risks.

The limited offer period closes soon on 25 June 2026. After this, the liquidity window at A$5.10 will close, and the path forward for Atlas Arteria will depend on the outcome of the bid and subsequent strategic moves.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 4%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.

View Original Announcement

The post Diamond Infraco's $5.10 offer for Atlas Arteria now unconditional appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• The off-market cash takeover offer from IFM is $5.10 per Atlas Arteria security.
• The offer is 12% below the $5.79 midpoint of the Independent Expert's valuation range of $5.39 to $6.20 per security.
• Atlas Arteria reconfirmed its 2026 ordinary distribution guidance of 40.0 cents per security.
• Any net proceeds from asset sales would be returned to securityholders in addition to the ordinary distribution.

What else do investors need to know?

Atlas Arteria's Independent Directors have strongly advised securityholders to reject IFM's current offer, arguing it does not reflect a full and fair value for the business, especially in light of the company's global toll road portfolio and ongoing asset-sale process.

The company is progressing the planned sale of part or all of its 66.67% stake in the Chicago Skyway, with agreements expected to be signed in the fourth quarter of 2026. Proceeds from this and any other divestments are intended to be distributed to shareholders, representing additional value on top of existing distribution targets.

Management also noted confidence that taxes arising from the Chicago Skyway transaction are expected to be immaterial, with efficient return-of-capital arrangements under consideration.

What's next for Atlas Arteria?

Atlas Arteria is targeting continued disciplined management, with a focus on long-term value creation and sustainable returns for its investors. The company reaffirmed its planned distribution of at least 40.0 cents per security in 2026, subject to ongoing business performance and market conditions.

Beyond the current offer period, Atlas Arteria will continue strategic asset reviews and may pursue further capital returns, while upholding its governance commitments and ensuring independent majority representation on its boards.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.

View Original Announcement

The post Atlas Arteria urges shareholders to reject IFM's $5.10 takeover bid appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• Offer price increased from $4.75 to $5.10 per security
• The new offer represents a 17.8% premium to the closing price on 24 April 2026
• Bidder's voting power in Atlas Arteria now stands at 34.59%
• The offer is unconditional except for 'no prescribed occurrences'
• Bidders authorised to acquire securities on-market at or below the offer price

What else do investors need to know?

The bidder has declared the $5.10 offer "best and final" in the absence of a competing proposal, meaning it won't be raised further unless another suitor emerges. Shareholders can also choose to sell on-market for T+2 settlement terms at or above the offer price, but should be aware that brokerage fees may apply.

Diamond Infraco has highlighted that the offer gives a cash certain value now, contrasted against the risks and uncertainty of Atlas Arteria's alternative plans, such as a potential Chicago Skyway sale. The company stressed that a sale has already been under consideration for over a year, with no firm outcome.

What's next for Atlas Arteria?

The offer remains open until 7:00pm on 25 June 2026, unless extended. If accepted, shareholders who go via the offer will generally receive payment within 21 days of the offer closing, while those selling on-market settle in two business days but forfeit further participation.

Looking ahead, the next key event will be the resolution of the sole remaining offer condition (no prescribed occurrences) and the board's recommendation. Shareholders are encouraged to review all documents and consider their options.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement

The post Atlas Arteria: Takeover offer lifted to $5.10 per security appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• The offer period for Diamond Infraco's takeover bid has been extended to 7:00pm (Sydney time) on Thursday, 25 June 2026.
• Several regulatory and material agreement conditions of the offer have been either fulfilled or waived.
• The bid remains subject to a small number of outstanding conditions, including no market fall and restrictions on distributions and major business changes.
• The new deadline for notice of the status of conditions is now 18 June 2026.

What else do investors need to know?

Diamond Infraco's extension gives Atlas Arteria shareholders a further week to consider the bid, replacing the previous closing date of 18 June 2026. Most regulatory hurdles have now been cleared, which means the offer is closer to being unconditional.

At the time of the latest statement, only a handful of conditions remain. These largely relate to market performance and ensuring Atlas Arteria does not undertake significant changes before the offer closes. This update was formally lodged with the Australian Securities and Investments Commission on 10 June 2026.

What's next for Atlas Arteria?

The focus now shifts to whether the remaining offer conditions are satisfied or waived ahead of the extended closing date. Shareholders can expect further updates by or before 18 June 2026 regarding the status of outstanding conditions.

Looking ahead, Atlas Arteria's board and shareholders will be weighing up the merits of the revised timeline and any developments in negotiations with Diamond Infraco as the offer nears its new closing date.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 4%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 1% over the same period.

View Original Announcement

The post Atlas Arteria takeover bid extended appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• The offer period for IFM's off-market takeover bid has been extended by one week, now closing at 7.00pm (Sydney) on 18 June 2026.
• Atlas Arteria maintains guidance for an ordinary distribution of 40.0 cents per security in 2026.
• The independent directors continue to recommend that securityholders reject the $4.75 and $5.10 per security offers.
• No announced increase in the bidder's voting power since extension; acceptances remain low.
• The bidder has not satisfied or waived any of the extensive conditions set out in its offer.

What else do investors need to know?

The company's second supplementary target's statement was released in response to the Fourth Supplementary Bidder's Statement from IFM. The Board states there is no urgency for securityholders to accept the bid, as IFM must give notice of its offer conditions at least seven days before closure.

Atlas Arteria confirms that the proceeds from any asset sales would be available to be returned to securityholders, in addition to its regular distribution schedule. The company encourages investors to seek independent financial advice and read all issued statements and expert reports before making decisions regarding the offer.

What's next for Atlas Arteria?

Atlas Arteria's directors restate their confidence in the company's long-term value, urging securityholders to remain patient. The company has emphasised ongoing discipline in capital management, pledging returns to securityholders through regular and special distributions as circumstances permit.

With the offer period extended, investors will have advance notice if the bid becomes unconditional. The Board will continue to keep shareholders updated as developments unfold in the takeover process.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 1% over the same period.

View Original Announcement

The post Atlas Arteria reiterates 'reject' on IFM bid, maintains 2026 distribution guidance appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• The independent directors unanimously recommend Atlas Arteria securityholders reject the $4.75 per security takeover offer from IFM.
• The Independent Expert's Report values Atlas Arteria at $5.39–$6.20 per security, higher than the current offer.
• The offer price is below Atlas Arteria's recent closing price of $5.04 (as at 1 June 2026).
• The IFM offer remains highly conditional and may extend up to 12 months.
• Bidder retains the right to increase the offer up to $5.10 within 12 months after the offer closes.

What else do investors need to know?

The Supplementary Target's Statement responds directly to IFM's Third Supplementary Bidder's Statement, reiterating that the offer is "too low, opportunistic and highly conditional". Atlas Arteria's independent directors maintain that the terms do not provide an appropriate premium for control or reflect the long-term value of its international toll road portfolio.

The Board highlights that accepting the offer now would prevent shareholders from selling on market for potentially higher prices during the lengthy offer period. Securityholders are encouraged to read the full Target's Statement and seek independent advice if considering their options.

What's next for Atlas Arteria?

Atlas Arteria's board will continue actively engaging with shareholders and monitoring developments related to IFM's bid. Investors can expect ongoing updates if circumstances change or if a revised offer is made.

The company also remains focused on disciplined management and sustainable long-term value creation through its established portfolio of toll road assets in France, Germany, and the United States.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.

View Original Announcement

The post Atlas Arteria responds to IFM with "reject" on takeover offer appeared first on The Motley Fool Australia.

Every one of the 11 market sectors is in the red today.

Losses range from 0.03% for the ASX communications sector to 2.47% for property shares.

The world is waiting for Iran's response to a US peace plan that would end the war and reopen the Strait of Hormuz.

Meanwhile, brokers have indicated new confidence in several ASX 200 shares with rating upgrades this week.

Let's take a look.

Lottery Corporation Ltd (ASX: TLC)

The Lottery Corporation share price is $5.33, down 0.5% today.

This ASX 200 consumer discretionary share has risen 2% in the year to date (YTD).

Morgans upgraded Lottery Corporation shares from hold to accumulate yesterday.

The broker raised its 12-month price target from $5.70 to $6, suggesting 12% upside from here.

Morgans said:

The Lottery Corporation (TLC) has secured a 40-year extension of its Victorian Public Lottery Licence to 30 June 2068, paying a $1.145bn upfront premium funded entirely by debt.

The duration and timing of the renewal was a mild surprise given the licence was historically offered on 10-year terms and wasn't expiring until June 2028.

We view the deal as strategically positive, but near-term earnings absorb the cost. 

Light & Wonder Inc (ASX: LNW)

The Light & Wonder share price is $110.18, up 7.3% today.

Over the past month, this ASX 200 gaming share has fallen 13%.

Morgans upgraded Light & Wonder shares to a buy rating yesterday.

The broker shaved its 12-month price target from $140 to $138.

This implies a healthy potential 25% upside ahead.

ANZ Group Holdings Ltd (ASX: ANZ)

The ANZ share price is $36.87, down 1.3% today.

Over the past month, this ASX 200 bank share has fallen 3.8%.

Morgans upgraded ANZ shares from a sell to trim rating this week.

The broker lifted its 12-month price target by 4% to $31.85.

This suggests a potential 13% downside ahead.

After reviewing the bank's 1H FY26 results, Morgans said:

1H26 revenues were flat on an underlying basis, but cost decline and credit impairment charges were better than expected.

Target price increased 4% to $31.85/sh, given 3-6% earnings upgrades and decision to recommence neutralising the DRP.

National Australia Bank Ltd (ASX: NAB)

The NAB share price is $38.53, down 2.5% today.

Over the past month, this ASX 200 financial share has fallen 13.5%.

Morgans upgraded NAB shares from a sell to a trim rating this week.

The broker lifted its 12-month price target by 4% to $36.10.

This implies a potential 6% moderation ahead.

Morgans said 1H FY26 earnings "were a mixed bag and a touch below expectations".

Westpac Banking Corp (ASX: WBC)

The Westpac share price is $37.84, down 1.9% for multiple reasons on Friday.

Over the past month, this ASX 200 bank share has fallen 9.8%.

Morgans upgraded Westpac shares from a sell to a trim rating this week.

The broker cut its price target by 3% to $33.07, implying a 13% fall ahead.

Morgans commented on Westpac's 1H FY26 results:

Strong volume momentum but earnings leverage dissipated with margin compression and credit risk pressures.

TechnologyOne Ltd (ASX: TNE)

The TechnologyOne share price is $28.37, up 3.4% on Friday.

Over the past month, this ASX 200 tech share has fallen 3.6%.

Bell Potter upgraded TechnologyOne shares to a buy rating yesterday.

The broker raised its 12-month price target from $31 to $31.75, suggesting 12% upside ahead.

Atlas Arteria Ltd (ASX: ALX)

The Atlas Arteria share price is $4.80, down 0.1% today.

This ASX 200 industrials stock surged recently on news of a hostile takeover bid from IFM Investors.

Atlas Arteria's independent directors have recommended that investors reject the $4.75 per share offer.

Morgans upgraded Atlas Arteria shares from trim to hold this week.

The broker said:

ALX recommended its investors ignore IFM's hostile off-market takeover bid, citing the offer price as too low, the timing opportunistic, and the offer highly conditional. It also disclosed it initiated a sale process for its interest in Chicago Skyway which, if successful, could be value accretive (at least to our valuation).

While the Chicago Skyway divestment process is underway we moderate our rating from TRIM to HOLD given potential for value realisation above what we consider to be the intrinsic value of the asset and hence driving our ALX valuation up close to where the share price is currently trading.

Morgans has a share price target of $4.22 on the toll roads operator.

This suggests a 12% downside from here.

The post 7 ASX 200 shares just upgraded this week appeared first on The Motley Fool Australia.

The market has rallied on hopes of a US-Iran peace deal.

Meanwhile, Morgans has updated its ratings and price targets on three ASX shares.

Let's check them out.

Minerals 260 Ltd (ASX: MI6)

The Minerals 260 share price is 75 cents, down 1.7% today but up 474% over 12 months.

In a new note, Morgans said the gold miner had awarded a building contract for a 400-person accommodation village at Bullabulling.

The broker said this marks "a key step toward development" for the ASX mineral explorer.

Ongoing drilling continues to support resource growth, conversion and strike continuity, reinforcing confidence in the scale and quality of the system.

As a result, our confidence in Bullabulling's commerciality strengthens and update our model to reflect a larger-scale operation …

We maintain our BUY rating and lift our price target to A$1.40ps (from A$1.20ps), driven by the increased scale and improved production profile under our revised development scenario.

Atlas Arteria Ltd (ASX: ALX)

The Atlas Arteria share price is $4.79, down 0.6% today but up 13% over the past month.

The recent gain is due to a hostile takeover bid from IFM Investors.

Atlas Arteria's independent directors have recommended that shareholders reject the offer of $4.75 per share.

Morgans moved from a trim to a hold rating this week. It has a share price target of $4.22 on the toll roads operator.

The broker said:

ALX recommended its investors ignore IFM's hostile off-market takeover bid, citing the offer price as too low, the timing opportunistic, and the offer highly conditional. It also disclosed it initiated a sale process for its interest in Chicago Skyway which, if successful, could be value accretive (at least to our valuation).

While the Chicago Skyway divestment process is underway we moderate our rating from TRIM to HOLD given potential for value realisation above what we consider to be the intrinsic value of the asset and hence driving our ALX valuation up close to where the share price is currently trading.

Super Retail Group Ltd (ASX: SUL)

The Super Retail share price is $11.20, down 4% today and down 16.4% over 12 months.

Morgans released a note today maintaining its hold rating on this ASX retail share. Its price target is $12.90.

The broker said:

SUL delivered a softer trading update, with all divisions seeing a deceleration in LFL sales through Mar/Apr (group LFL -2%) and group gross margin compression.

Weaker consumer sentiment from inflationary pressures (fuel and rates) weighed over the key Easter period as the promotional environment remains intense.

Limited earnings visibility and a challenging backdrop persist, with capital management initiatives unlikely to feature in FY26.

The post Buy, hold, or sell? Minerals 260, Atlas Arteria, Super Retail shares appeared first on The Motley Fool Australia.

The modest gain follows a key update on a takeover approach from IFM Investors. Atlas Arteria's independent directors have formally recommended that securityholders reject IFM's hostile offer. They argue it undervalues the business and comes with significant conditions.

IFM's proposal stands at $4.75 per stapled security, which is below the current trading price, a factor that may also be supporting the share price.

So, what exactly did Atlas Arteria say?

The board described the bid as opportunistic, noting it comes at a time of recent market volatility and follows a period where the ASX 200 stock has traded well above the offer price over the past year.

Independent directors believe the proposal fails to reflect the true value of Atlas Arteria's global toll road portfolio and its future growth potential. The company owns and operates major infrastructure assets across North America and Europe, generating stable, inflation-linked cash flows.

Over 50 extra conditions

Another major sticking point is the structure of the offer itself. The $7 billion ASX 200 stock highlighted that IFM's takeover proposal includes more than 50 separate sub-conditions, some of which are already incapable of being satisfied. That level of conditionality introduces uncertainty and reduces the likelihood of the deal proceeding in its current form.

In a separate but related development, Atlas Arteria has issued a Right of First Offer over its interest in the Chicago Skyway. While not directly tied to the takeover bid, this move is relevant to certain conditions within IFM's proposal. It also signals the company is continuing to actively manage its asset portfolio.

Exploring asset recycling

Management also reiterated that it is exploring broader value-enhancing initiatives for investors. These include potential asset recycling and strategic options for its US operations, which could unlock additional value over time.

Chair Debbie Goodin was direct in her assessment of the bid:

This hostile, highly conditional takeover offer from IFM is opportunistic and materially undervalues Atlas Arteria. The Offer is designed to accelerate IFM's creep to effective control of Atlas Arteria without paying a fair premium to securityholders. The Independent Directors of Atlas Arteria recommend that securityholders reject the Offer. The Boards and management remain focused on continuing to deliver on the strategy to optimise company value and create value for all securityholders.

What next for the ASX 200 stock?

Atlas Arteria is now preparing a formal Target's Statement, which will include an independent expert's report and outline the board's detailed recommendation. This will be provided to investors at least 14 days before the offer closes.

Looking at recent performance, Atlas Arteria shares have rallied nearly 14% over the past month. However, over the past year, the ASX 200 stock is still down around 7%, lagging the S&P/ASX 200 Index, which has gained about 6%.

For now, the market appears to be backing the board's view that the offer undervalues the company. That could explain why the share price is holding above the bid.

The post Which ASX 200 stock is lifting after a hostile takeover update? appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• IFM's hostile takeover offer is set at A$4.75 per stapled security (potentially A$5.10 if IFM's interest exceeds 45% before close).
• Offer price is below Atlas Arteria's previous closing price of A$4.79 (5 May 2026).
• The offer premium is less than 10% compared to the pre-offer closing price and around 3% above the 12-month average price.
• Atlas Arteria reaffirms distribution guidance of 40.0 cents per security for 2026.
• Each independent director intends to reject IFM's offer for their own ALX securities.

What else do investors need to know?

The board considers IFM's offer opportunistic, given recent market volatility and the share price trading well above the offer in the past year. Independent directors say the offer undervalues the company's global toll road portfolio and future growth opportunities. The company also notes IFM's current offer comes with over 50 separate sub-conditions, some of which are already incapable of being satisfied.

Atlas Arteria has issued a Right of First Offer in relation to its Chicago Skyway interest, a move unrelated to IFM's bid but relevant to the bid's conditions. The company continues to explore value-enhancing initiatives for securityholders, including asset recycling and potential strategic alternatives for its US assets.

What did Atlas Arteria management say?

Chair Debbie Goodin said:

This hostile, highly conditional takeover offer from IFM is opportunistic and materially undervalues Atlas Arteria. The Offer is designed to accelerate IFM's creep to effective control of Atlas Arteria without paying a fair premium to securityholders. The Independent Directors of Atlas Arteria recommend that securityholders reject the Offer. The Boards and management remain focused on continuing to deliver on the strategy to optimise company value and create value for all securityholders.

What's next for Atlas Arteria?

Atlas Arteria is preparing a detailed Target's Statement for securityholders, which will include an independent expert's report and set out the board's formal recommendation to reject IFM's offer. The statement will be provided at least 14 days before the offer closes.

The company says it will continue to update investors on material developments and remains focused on its strategy to optimise its asset portfolio and deliver distribution guidance.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria's shares have declined 7%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Atlas Arteria directors urge investors to reject IFM's takeover offer appeared first on The Motley Fool Australia.

The dip comes after a sharp 13% jump on Monday, when markets reacted enthusiastically to an initial approach from IFM Investors. That early bid sparked immediate re-rating of the toll road operator, which owns stakes in major assets including the APRR toll road network in France.

Now, IFM is back and the proposal is getting more serious.

Refined takeover push

Atlas Arteria is one of the world's largest listed toll road groups, with long-term, inflation-linked cash flows supported by high-quality infrastructure assets. That predictable earnings profile has long made it attractive to infrastructure investors.

IFM Investors, already a major shareholder with a 35% stake, has been steadily increasing its interest in the remaining Atlas Arteria shares. Its latest move is not just a repeat of the initial offer of $4.75 cash per security, which may be increased by 35 cents per share if IFM's interest rises above 45% before closing.

Today's bid is a more refined and structured proposal aimed at progressing discussions toward a potential full acquisition. While still non-binding, the updated bid is understood to provide clearer terms and stronger intent, signalling that IFM is willing to pursue control rather than simply test valuation levels.

For Atlas Arteria shareholders, that shift matters. Early-stage takeover interest often attracts speculation, but refinements typically indicate the bidder is moving from "exploring" to "serious pursuit."

Market excitement, then caution

The market's reaction has followed a familiar pattern. The initial approach for the ASX transport stock sparked a strong re-rating as investors priced in takeover potential and the likelihood of a premium to market value.

But the latest update has seen some cooling, with the price of Atlas Arteria shares drifting slightly lower after the sharp Monday spike. That's not unusual. Once initial excitement fades, investors often reassess the probability, timing, and potential price of any deal being completed.

What happens next?

The key question now is whether IFM will escalate further or move toward a binding offer.

As a major existing shareholder, IFM already has deep knowledge of Atlas Arteria's assets and performance. That can speed up due diligence and improve confidence in valuation, but it doesn't guarantee a deal will proceed.

Any formal offer would still require board consideration, regulatory approvals, and agreement on price. All of which could take time.

Foolish Takeaway

The ASX 200 stock remains anchored by long-term infrastructure assets and stable cash flows, which is exactly what makes it attractive in the first place.

The latest move from IFM suggests takeover interest is not fading, it's evolving. But until a binding offer emerges, volatility is likely to continue as investors weigh speculation against fundamentals.

The post Which ASX 200 stock is slipping on a sharpened takeover bid? appeared first on The Motley Fool Australia.

What did Atlas Arteria report?

• Received an unsolicited takeover offer from IFM Global Infrastructure Fund at $4.75 cash per security
• IFM Investors currently owns about 35% of Atlas Arteria securities
• The offer is conditional on various approvals and consents
• Offer may be increased by 35 cents per security if IFM's interest rises above 45% before closing
• Atlas Arteria's closing price before the offer announcement was $4.82 per security

What else do investors need to know?

The Atlas Arteria Board emphasised that it did not solicit this proposal and recommends securityholders take no action at this stage. An Independent Board Committee has been established to carefully consider the offer and provide guidance to investors in due course.

IFM's takeover bid is subject to multiple conditions, some involving third-party consents that may be difficult to obtain. Securityholders will receive further information through a Bidder's Statement from IFM, to be followed by a Target's Statement from Atlas Arteria.

Annual General Meetings for Atlas Arteria Limited and Atlas Arteria International Limited will be held on 13 May 2026. Security holders are encouraged to vote according to director recommendations.

What's next for Atlas Arteria?

Atlas Arteria has established an Independent Board Committee to thoroughly review IFM's offer and assess all available options for securityholders. The company will issue its Target's Statement after receiving IFM's Bidder's Statement, expected in mid-May.

In the meantime, investors are advised to wait for the company's formal recommendation before making any decisions. Atlas Arteria will keep securityholders updated on significant developments through direct communication and ASX announcements.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 8%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Atlas Arteria receives takeover offer from IFM Investors appeared first on The Motley Fool Australia.

After more reports and key announcements this week, the team at Morgans have provided fresh guidance on these ASX shares. 

Let's see if Morgans sees these ASX shares as a buy, hold, or sell. 

6K Additive Inc (ASX: 6KA)

6K Additive is a US-based manufacturer, upcycling metal scrap into premium metal powders and alloying additives.

Yesterday, the company released its Quarterly Activities and Cash Flow Report. 

The team at Morgans said the company delivered a strong March quarter update, with revenue up 88% to US$6.2m. 

This implies an annualised run-rate of ~US$25m, up from ~US$22m in 4Q25, driven by solid demand from both new and existing customers. The run-rate is also ahead of our CY26 revenue forecast of US$22.8m, with the company capturing market share and improving operational metrics. B

oth the Powder (+100%) and Alloy (+70%) products divisions delivered strong revenue growth on the pcp, with a higher order backlog supporting sales momentum over coming months.

Based on this guidance, Morgans said it thinks the company is well-positioned to benefit from strong demand in metal additive manufacturing and US initiatives to reshore critical minerals, supported by its fully domestic powder production, which reduces reliance on foreign-controlled feedstock. 

The broker has retained its speculative buy rating and $1.30 price target on these ASX shares. 

This target is approximately a 71% upside from today's share price. 

Atlas Arteria Ltd (ASX: ALX)

This ASX company is a global owner, operator, and developer of toll roads. 

It received an unsolicited, off-market bid earlier this week from infrastructure investor IFM Investors.

This sent the stock price surging 14% higher on Monday. 

The team at Morgans said, given IFM's existing large (and growing) stake in ALX and the OTPP poison pill, we believe it is unlikely that a counter-bidder will emerge. 

Hence, our assessment is that risk at current prices is skewed to the downside ($4.22/share) rather than upside ($5.10/share). TRIM into current share price strength.

ALX shares are currently exchanging hands for $4.84. 

Imricor Medical Systems Inc (ASX: IMR)

Imricor is a medical device company that engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures.

The company just released a 1Q26 cash flow report.

Morgans said while sales remain modest, the underlying cash burn was higher than the previous quarter and expected to normalise around US$6m. 

During the quarter one-off costs related to the purchase of 40 generators which were part of an in-house transitioning process. Cash at the end of the quarter was US$32.9m, representing 5.5 quarters of underlying cash burn.

We have made no changes to forecasts. However, a higher risk-free rate (house view), sees our DCF valuation reduce to A$2.63 (was $2.71). We maintain our SPECULATIVE BUY recommendation with numerous catalysts approaching.

This indicates a 35% upside from today's stock price of $1.94. 

The post Are these ASX shares a buy, hold or sell according to Morgans after key updates? appeared first on The Motley Fool Australia.

After staying in red territory all session, the ASX 200 ended up finishing down 0.23%. That leaves the index at 8,766.4 points.

This rather depressing start to the Australian trading week comes after a more nuanced end to the American trading week on Friday night (our time).

The Dow Jones Industrial Average Index (DJX: .DJI) was in the same mould as the ASX, dropping 0.16%.

However, the tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) fared far better, roaring 1.63% higher.

But let's get back to this week and our local markets now, and check out what was happening amongst the different ASX sectors this Monday.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.